Compare ICCC & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICCC | NTRB |
|---|---|---|
| Founded | 1982 | 2016 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.5M | 54.1M |
| IPO Year | 1995 | N/A |
| Metric | ICCC | NTRB |
|---|---|---|
| Price | $6.54 | $4.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 12.1K | 9.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.33 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $26,493,169.00 | N/A |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | $32.15 | ★ N/A |
| Revenue Growth | ★ 51.64 | N/A |
| 52 Week Low | $4.32 | $3.96 |
| 52 Week High | $7.60 | $11.68 |
| Indicator | ICCC | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 53.29 | 41.43 |
| Support Level | $6.13 | N/A |
| Resistance Level | $6.87 | $4.50 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 68.57 | 10.10 |
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.